Susquehanna Fundamental Investments LLC Invests $576,000 in Repligen Co. (NASDAQ:RGEN)

Susquehanna Fundamental Investments LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 4,000 shares of the biotechnology company's stock, valued at approximately $576,000.

Other institutional investors also recently made changes to their positions in the company. Signaturefd LLC lifted its stake in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Repligen in the 4th quarter worth approximately $29,000. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the period. Global Retirement Partners LLC grew its position in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Repligen in the 4th quarter valued at approximately $55,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of several recent analyst reports. Royal Bank of Canada decreased their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Thursday. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Trading Down 1.7 %

Shares of NASDAQ RGEN traded down $2.11 during midday trading on Friday, reaching $125.74. The company had a trading volume of 167,555 shares, compared to its average volume of 746,372. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a one year low of $102.96 and a one year high of $182.52. The firm's fifty day moving average price is $135.66 and its 200-day moving average price is $145.46. The stock has a market cap of $7.06 billion, a PE ratio of -246.55, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $0.28 earnings per share. On average, equities research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.